Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antiplatelet agents

H D White1, J K French, C J Ellis

  • 1Green Lane Hospital, Auckland, New Zealand.

Australian and New Zealand Journal of Medicine
|October 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dental Societies and Dental Literature: Read before the Eighth District Dental Society of the State of New York.

The Independent practitioner·2023
Same author

Common genetic variants do not predict recurrent events in coronary heart disease patients.

BMC cardiovascular disorders·2022
Same author

Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome.

Journal of internal medicine·2021
Same author

OakEcol: A database of Oak-associated biodiversity within the UK.

Data in brief·2019
Same author

Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.

Journal of internal medicine·2017
Same author

UK service level audit of insulin pump therapy in paediatrics.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same journal

Gastroenterological Society of Australia, Annual Scientific Meeting, May 1980.

Australian and New Zealand journal of medicine·2020
Same journal

'A touch of sugar'--a dangerous euphemism still alive and well.

Australian and New Zealand journal of medicine·2001
Same journal

Silent myocardial ischaemia following methysergide overdose.

Australian and New Zealand journal of medicine·2001
Same journal

Extensive jugular and upper limb thrombosis in a patient with factor V Leiden mutation and non-Hodgkin's lymphoma.

Australian and New Zealand journal of medicine·2001
Same journal

Visual loss as the presenting feature of giant cell arteritis.

Australian and New Zealand journal of medicine·2001
Same journal

Lymphoproliferative disease causing angioedema--an uncommon association.

Australian and New Zealand journal of medicine·2001
See all related articles

Aspirin and newer antiplatelet agents target platelet aggregation pathways. Glycoprotein IIb/IIIa inhibitors show promise as adjunctive therapy for acute coronary syndromes and secondary prevention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Aspirin is a standard therapy for acute myocardial infarction (AMI) and unstable angina, and for secondary prevention in stable angina.
  • Aspirin inhibits cyclooxygenase-1, reducing thromboxane A2 production and thus one pathway of platelet aggregation.
  • Other antiplatelet agents like ticlopidine and clopidogrel inhibit adenosine diphosphate-mediated aggregation, affecting only one of many platelet activation pathways.

Purpose of the Study:

  • To review the role of antiplatelet agents in managing acute coronary syndromes.
  • To discuss the mechanisms of action of aspirin, ADP inhibitors, and glycoprotein IIb/IIIa inhibitors.
  • To highlight the evolving role of glycoprotein IIb/IIIa inhibitors in angioplasty, unstable angina, and AMI.

Main Methods:

Related Experiment Videos

  • Review of clinical trials evaluating antiplatelet agents.
  • Discussion of the mechanisms of platelet aggregation and inhibition.
  • Analysis of the characteristics and trial data for various antiplatelet drug classes.

Main Results:

  • Aspirin inhibits a single pathway of platelet aggregation.
  • Ticlopidine and clopidogrel target adenosine diphosphate-mediated aggregation.
  • Glycoprotein IIb/IIIa inhibitors block the final common pathway of platelet aggregation and are used as adjunctive therapy.

Conclusions:

  • Glycoprotein IIb/IIIa inhibitors have a significant role in adjunctive therapy for angioplasty and acute coronary syndromes.
  • Ongoing trials are evaluating intravenous and oral glycoprotein IIb/IIIa inhibitors for broader clinical application.
  • These agents are expected to be increasingly integrated into the management of patients with acute coronary syndromes.